Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)

• Published in: Journal of blood medicine Vol. 10; pp. 335 - 340
• Main Authors: Rajpurkar, Madhvi, Croteau, Stacy E, Boggio, Lisa, Cooper, David L
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2019; Dove; Dove Medical Press
• Subjects: acquired hemophilia; Cardiovascular disease; Clinical trials; Congenital diseases; congenital factor VII deficiency; congenital hemophilia with inhibitors; Ethics; Glanzmann’s thrombasthenia; Hemophilia; Hospitals; Licenses; Original Research; Pediatrics; postmarketing surveillance; Risk factors; Sensitivity analysis; Surveillance; Thromboembolism; Thrombosis; United States > US; Detroit Michigan; Michigan; postmarketing surveillance; congenital factor VII deficiency; congenital hemophilia with inhibitors; acquired hemophilia; Glanzmann’s thrombasthenia
• ISSN: 1179-2736; 1179-2736
• DOI: 10.2147/JBM.S219573

Recombinant activated factor VII (rFVIIa; NovoSeven RT; Novo Nordisk A/S, Bagsvaerd, Denmark) is approved in the United States for the treatment of bleeding and perioperative management in congenital hemophilia with inhibitors (CHwI), acquired hemophilia (AH), congenital factor VII (FVII) deficiency, and Glanzmann's thrombasthenia (GT) with refractoriness to platelets. The aim of the current analysis was to review clinical trials and registries pre- and post-licensure for each indication to establish the estimated rate of thrombosis and then to establish the association of all reported thrombotic events (TEs) with certain risk factors listed for many years in the prescribing information (PI). A retrospective safety assessment of both clinical trials and registries used to support licensure and postmarketing surveillance was performed. The rate of thrombosis was calculated in the 4 indicated disorders and an assessment of TE risk factors was conducted through a review of all narratives within those indications in the safety database. In clinical trials and registries used to support licensure and in postmarketing surveillance, the overall rate of thrombosis was 0.17% of 12,288 bleeding and surgical episodes. The specific risk by indication was 0.11% for CHwI, 0.82% for FVII deficiency, 0.19% for GT, and 1.77% for AH. The most common associated risk factor-"elderly" (29%), defined in the PI as age ≥65 years-was particularly prevalent in patients with AH. TE was also frequently reported with concomitant cardiac or vascular disease (18%) and use of activated prothrombin complex concentrates (18%). Data show that the rate of TEs within the 4 licensed indications is low, as was originally described in the US PI from 1999 to 2009. It has remained stable over time during postapproval surveillance in multiple US and global registries with active surveillance for safety information across the 4 approved indications.